Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter McIntyre

Showing results (221-230 of 235) with videos related to

Pageof 24
Sort By:
Nature Communications|February 16, 2023
Optimal age targeting for pneumococcal vaccination in older adults; a modelling studyDeus Thindwa, Samuel Clifford, Jackie Kleynhans, et al.
The Lancet. Infectious Diseases|June 30, 2022
Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled trialsAmanda Jane Leach, Nicole Wilson, Beth Arrowsmith, et al.
Vaccine|July 6, 2022
The effect of needle length and skin to deltoid muscle distance in adults receiving an mRNA COVID-19 vaccineThomas Hills, Aimee Paterson, Rebecca Woodward, et al.
Medrxiv : the Preprint Server for Health Sciences|July 29, 2024
Spatial and temporal transmission dynamics of respiratory syncytial virus in New Zealand before and after the COVID-19 pandemicLauren Jelley, Jordan Douglas, Meaghan O'Neill, et al.
Journal of Great Lakes Research|July 24, 2018
Ecosystem services in the Great LakesAlan D Steinman, Bradley J Cardinale, Wayne R Munns, et al.
Journal of Medicinal Chemistry|May 17, 2002
Nonpeptide bradykinin B2 receptor antagonists: conversion of rodent-selective bradyzide analogues into potent, orally-active human bradykinin B2 receptor antagonistsEdward K Dziadulewicz, Timothy J Ritchie, Allan Hallett, et al.
Vaccine|August 25, 2023
Erratum to "Real world impact of 13vPCV in preventing invasive pneumococcal pneumonia in Australian children: A national study" [Vaccine 41(1) (2023) 85-91]Nusrat Homaira, Roxanne Strachan, Helen Quinn, et al.
Vaccine|November 18, 2022
Real world impact of 13vPCV in preventing invasive pneumococcal pneumonia in Australian children: A national studyNusrat Homaira, Roxanne Strachan, Helen Quinn, et al.
The Journal of Infectious Diseases|February 24, 2025
Comparison of the incidence and risk factors of COVID-19 and influenza associated acute respiratory illnesses: Results of the SHIVERS-II, III, IV prospective community cohort studyQ Sue Huang, Tim Wood, Nayyereh Aminisani, et al.
Plos Medicine|June 3, 2024
Hearing loss in Australian First Nations children at 6-monthly assessments from age 12 to 36 months: Secondary outcomes from randomised controlled trials of novel pneumococcal conjugate vaccine schedulesAmanda Jane Leach, Nicole Wilson, Beth Arrowsmith, et al.
Pageof 24

Showing results (221-230 of 235) with videos related to

Sort By:
Pageof 24
Nature Communications|February 16, 2023
Optimal age targeting for pneumococcal vaccination in older adults; a modelling studyDeus Thindwa, Samuel Clifford, Jackie Kleynhans, et al.
The Lancet. Infectious Diseases|June 30, 2022
Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled trialsAmanda Jane Leach, Nicole Wilson, Beth Arrowsmith, et al.
Vaccine|July 6, 2022
The effect of needle length and skin to deltoid muscle distance in adults receiving an mRNA COVID-19 vaccineThomas Hills, Aimee Paterson, Rebecca Woodward, et al.
Medrxiv : the Preprint Server for Health Sciences|July 29, 2024
Spatial and temporal transmission dynamics of respiratory syncytial virus in New Zealand before and after the COVID-19 pandemicLauren Jelley, Jordan Douglas, Meaghan O'Neill, et al.
Journal of Great Lakes Research|July 24, 2018
Ecosystem services in the Great LakesAlan D Steinman, Bradley J Cardinale, Wayne R Munns, et al.
Journal of Medicinal Chemistry|May 17, 2002
Nonpeptide bradykinin B2 receptor antagonists: conversion of rodent-selective bradyzide analogues into potent, orally-active human bradykinin B2 receptor antagonistsEdward K Dziadulewicz, Timothy J Ritchie, Allan Hallett, et al.
Vaccine|August 25, 2023
Erratum to "Real world impact of 13vPCV in preventing invasive pneumococcal pneumonia in Australian children: A national study" [Vaccine 41(1) (2023) 85-91]Nusrat Homaira, Roxanne Strachan, Helen Quinn, et al.
Vaccine|November 18, 2022
Real world impact of 13vPCV in preventing invasive pneumococcal pneumonia in Australian children: A national studyNusrat Homaira, Roxanne Strachan, Helen Quinn, et al.
The Journal of Infectious Diseases|February 24, 2025
Comparison of the incidence and risk factors of COVID-19 and influenza associated acute respiratory illnesses: Results of the SHIVERS-II, III, IV prospective community cohort studyQ Sue Huang, Tim Wood, Nayyereh Aminisani, et al.
Plos Medicine|June 3, 2024
Hearing loss in Australian First Nations children at 6-monthly assessments from age 12 to 36 months: Secondary outcomes from randomised controlled trials of novel pneumococcal conjugate vaccine schedulesAmanda Jane Leach, Nicole Wilson, Beth Arrowsmith, et al.
Pageof 24